Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Phase 4

Completed

Conditions: Mild to Moderate Alzheimer's Disease

Interventions: Drug: Rivastigmine Patch

First Posted Date: 2016-03-09

Last Posted Date: 2019-09-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT02703636

Locations: 🇯🇵
Novartis Investigative Site, Okayama, Japan

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Phase 3

Completed

Conditions: Cushing's Disease

Interventions: Drug: osilodrostat
Drug: osilodrostat Placebo

First Posted Date: 2016-03-03

Last Posted Date: 2021-11-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT02697734

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
🇺🇸
Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States
🇺🇸
University of Colorado Endocrinology Clinical Trials Unit, Aurora, Colorado, United States

and more 4 locations

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

Phase 3

Completed

Conditions: Non-radiographic Spondyloarthritis

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2016-03-02

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT02696031

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study of CLR325 in Chronic Stable Heart Failure Patients.

Phase 2

Completed

Conditions: Chronic Stable Heart Failure

Interventions: Drug: CLR325
Other: Placebo

First Posted Date: 2016-03-02

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT02696967

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Phase 4

Completed

Conditions: Hearth Failure With Reduced Ejection Fraction (HFrEF)

Interventions: Drug: LCZ696 (sacubitril/valsartan)

First Posted Date: 2016-02-24

Last Posted Date: 2019-06-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT02690974

Locations: 🇨🇦
Novartis Investigative Site, St-Lambert, Canada

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Phase 4

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Secukinumab 300 mg
Biological: Placebo

First Posted Date: 2016-02-24

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 91

Registration Number: NCT02690701

Locations: 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Phase 2

Completed

Conditions: Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Pleomorphic Xanthoastrocytoma
Angiocentric Glioma
Giant Cell Astrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma
Oligodendroglioma, Childhood
Glioblastoma
Astrocytoma
Pilocytic Astrocytoma

Interventions: Drug: Dabrafenib
Drug: Carboplatin
Drug: trametinib
Drug: Vincristine

First Posted Date: 2016-02-17

Last Posted Date: 2023-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 151

Registration Number: NCT02684058

Locations: 🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago, Illinois, United States
🇺🇸
Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 8 locations

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Phase 1

Completed

Conditions: Advanced Malignancies

Interventions: Drug: PDR001

First Posted Date: 2016-02-09

Last Posted Date: 2018-06-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT02678260

Locations: 🇯🇵
Novartis Investigative Site, Kobe-city, Hyogo, Japan

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

Phase 2

Completed

Conditions: Chronic Kidney Disease (CKD)

Interventions: Drug: Placebo
Drug: LHW090

First Posted Date: 2016-02-09

Last Posted Date: 2021-10-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT02678000

Locations: 🇩🇪
Novartis Investigative Site, Mannheim, Germany

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Phase 2

Completed

Conditions: Pediatric Heart Failure

Interventions: Drug: LCZ696
Drug: Enalapril
Drug: Placebo of Enalapril
Drug: Placebo of LCZ696

First Posted Date: 2016-02-09

Last Posted Date: 2023-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 393

Registration Number: NCT02678312

Locations: 🇹🇷
Novartis Investigative Site, Konak, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy